A multistep HDC regimen was designed as first-line chemotherapy for MBC. Twenty-four @entity1 with MBC and no previous chemotherapy for metastatic disease were treated with high-dose @entity786 (5000 mg/m2), and @entity2879 (1000 mg/m2) (CyVP16), followed by @entity1261 ( @entity1261 ). Peripheral blood stem cells (PBSCs) were collected. Subsequently @entity1 received @entity786 (6000 mg/m2), @entity11678 (500 mg/m2) and @entity3003 (800 mg/m2) (CTCb) with hematopoietic rescue. Upon recovery from hematopoietic and gastrointestinal @entity137 three cycles of @entity632 (50 mg/m2) and @entity1311 (150 mg/m2) were delivered. After CyVP16 42% of @entity1 developed @entity1398 fevers. There was one documented episode of @entity2259 . @entity1 received CTCb 32 days after starting CyVP16. After CTCb the median number of days to ANC >5 x 10(9)/l was 10 and to a platelet count >20 x 10(9)/l was 14. Neutropenic fevers developed in 16 @entity1 . There were no @entity548 episodes. A total of 69 cycles of @entity632 and @entity1311 were delivered (87% of planned). The median time from PBSC infusion to the first cycle was 38 days. The median time to the second cycle was 27 days and to the last cycle was 24 days. One @entity1 developed @entity712 . Two episodes of @entity1398 fevers were observed. No @entity137 -related deaths were observed. Grafts are stable at 6 months post transplantation. This multistep regimen is feasible with acceptable @entity137 .

High-dose chemotherapy and autologous stem cell support followed by post-transplant XXXX and @entity1311 as initial therapy for metastatic breast cancer: hematopoietic tolerance and efficacy.

@entity1 :: ('9606', 'Species') :: ['patients', 'Patients', 'patient'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'granulocyte colony-stimulating factor'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhagic'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity11678 :: ('MESH:D013852', 'Chemical') :: ['thiotepa'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['taxol'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenic'] @entity2259 :: ('MESH:D016470', 'Disease') :: ['bacteremia']
@entity632 :: (MESH:D004317,Chemical) :: ['doxorubicin']
